Text and Data Mining valid from 2019-01-01
Received: 13 October 2018
Accepted: 13 November 2018
First Online: 17 January 2019
Conflict of interest
: J.W.S. is an unpaid member of the Scientific Advisory Board of PsyBrain Inc. and the Bipolar/Depression Research Community Advisory Panel of 23andMe. H.R.K. has been an advisory board member, consultant, or continuing medical education speaker for Indivior, Lundbeck, and Otsuka. He is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was sponsored in the past 3 years by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. R.C.K. received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. R.C.K is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. The remaining authors declare that they have no conflict of interest.